Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2014

View Archived Issues

A non-cancerous FGF-19 variant for the treatment of liver disease

Panther secures option agreement on numonafide with Northwestern University

Targazyme receives SBIR award to study TZ-101-treated stem cell therapy in oral mucositis

Avanir initiates phase II study of AVP-786 in major depressive disorder; updates on AVP-923

Scientists in the U.S. patent novel inhibitors of Rho GTPase activation

New NS5B inhibitors prepared by Merck & Co.

Sientists at Cortendo patent new cytochrome P450 inhibitors

Identification of a transporter protein central to the erythrocytic cycle in Plasmodium parasites

Actinogen to acquire Corticrine

Saniona extends collaboration with Janssen Pharmaceutica

Velphoro receives marketing authorization in Europe

Merck & Co. divulges new mGlu4R PAMs

Takeda Pharmaceutical describes new M4 receptor agonists

Novel class of pan-pim inhibitors as potential oncolytics presented by Amgen

Live cell encapsulation technology plus low dose anticancer drugs, a novel approach

Bellcium Pharmaceuticals completes Series C financing

RedHill Biopharma amends protocol for phase III H. pylori study of RHB-105

FDA grants priority review to ivabradine for chronic heart failure

MEDI-6383 to be evaluated in phase I trial in patients with solid tumors

FDA grants orphan drug status to Iressa and Zelboraf for cancer

DC Bead approved in China for tumor embolization

Second DSMB review recommends continuation of GRASPA-ML study

Biothera receives NIH grant to continue development of antifungal vaccine

European Commission approves Bristol-Myers Squibb's Daklinza for HCV

Repros Therapeutics' Androxal superior to AndroGel in pivotal phase III trial in hypogonadism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...